Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca : India to miss end-July vaccination target as Bharat Biotech lags

07/26/2021 | 05:40am EDT
FILE PHOTO: Door-to-door vaccination drive in Banaskantha district

NEW DELHI (Reuters) - India will miss a target to administer over a half billion COVID-19 vaccine doses by the end of the month as Bharat Biotech - maker of its only approved homegrown shot - struggles to boost output, an analysis of government data showed on Monday.

India has undertaken one of the world's largest vaccination drives and has so far distributed some 430 million doses - more than any country except China, but less than many countries relative to its population.

The government said in May it would make 516 million shots available by the end of July. It wants to inoculate all its estimated 944 million adults by December.

To meet the July-end target, however, authorities will have to more than triple average daily vaccinations to 14 million doses. But that will not be possible, based on the latest supply projections for Bharat Biotech's Covaxin vaccine.

The government had been counting on deliveries of 60 million to 70 million Covaxin doses monthly from July or August.

But Bharat Biotech will only supply 25 million doses this month and 35 million in August as a new production line in the southern city of Bengaluru takes time to come online, Health Minister Mansukh Mandaviya told parliament last week.

Mandaviya added that the supply shortfall "would not affect our immunisation programme".

The health ministry did no immediately respond to a request for comment. Bharat Biotech declined to comment on its production.

The government is counting on 500 million doses of another vaccine from the Serum Institute of India (SII) and 400 million doses from Bharat Biotech between August and December for its vaccination campaign.

India's drug regulator controversially approved Bharat Biotech's Covaxin for emergency use in early January without efficacy data. But it has missed nearly all supply commitments to the government.

Immunisation efforts have also been hobbled by a delayed rollout of Russia's Sputnik V vaccine. And legal obstacles have prevented India from receiving U.S. donations of Moderna or Pfizer vaccines.

After halting exports in mid-April to meet domestic demand, SII meanwhile has nearly doubled output in the past three months.

Nearly 88% of all vaccine doses administered in India to date have been SII's Covishield shot, a version of the AstraZeneca vaccine.

The government expects the company to raise supplies of its Covishield vaccine to about 120 million doses in August from 100 million doses in June.

(Reporting by Krishna N. Das; Editing by Joe Bavier)

By Krishna N. Das

ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -1.24% 8461 Delayed Quote.15.70%
MODERNA, INC. -6.02% 384.21 Delayed Quote.267.77%
All news about ASTRAZENECA PLC
10:10aFTSE 100 Falls as Rising Energy Prices and Higher Bond Yields Prompt Global Selloff
09:48aFTSE 100 Flat, Wickes Shares Look Cheap Given its High Quality
08:42aASTRAZENECA : Credit Suisse maintains a Buy rating
08:26aSANOFI : - New research presented at IDWeek 2021 reinforces Sanofi :'s robust vaccines pip..
07:50aASTRAZENECA : Receives a Buy rating from Jefferies
07:06aASTRAZENECA : 300,000 Covid-19 Jabs Land in Namibia
06:32aASTRAZENECA : Saphnelo is a first-in-class type I interferon receptor antibody shown to re..
06:06aASTRAZENECA : Ghana Takes Custody of 1.5 Astrazeneca Doses Donation From Germany
05:06aASTRAZENECA : Govt - 4.7 Million Eligible Nigerians Have Received First Dose of Covid-19 V..
04:15aASTRAZENECA : Secures Japanese Regulatory Approval for Saphnelo as Treatment for Systemic ..
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2021 35 527 M - -
Net income 2021 5 009 M - -
Net Debt 2021 24 280 M - -
P/E ratio 2021 32,1x
Yield 2021 2,46%
Capitalization 178 B 178 B -
EV / Sales 2021 5,69x
EV / Sales 2022 4,61x
Nbr of Employees 76 100
Free-Float 96,3%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 27
Last Close Price 114,74 $
Average target price 136,23 $
Spread / Average Target 18,7%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC15.70%181 937
JOHNSON & JOHNSON3.45%429 542
ROCHE HOLDING AG9.24%319 352
PFIZER, INC.18.36%244 283
NOVO NORDISK A/S48.08%227 557